<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:17:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8733847" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8733847</identifier>
        <datestamp>2022-01-20</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id>
              <journal-title-group>
                <journal-title>JAMA Psychiatry</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2168-622X</issn>
              <issn pub-type="epub">2168-6238</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8733847</article-id>
              <article-id pub-id-type="pmcid">PMC8733847</article-id>
              <article-id pub-id-type="pmc-uid">8733847</article-id>
              <article-id pub-id-type="pmid">34817561</article-id>
              <article-id pub-id-type="pmid">34817561</article-id>
              <article-id pub-id-type="doi">10.1001/jamapsychiatry.2021.3422</article-id>
              <article-id pub-id-type="publisher-id">yoi210068</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="domain" specific-use="print">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="featured" specific-use="electronic">
                  <subject>Featured</subject>
                </subj-group>
                <subj-group subj-group-type="online-first">
                  <subject>Online First</subject>
                </subj-group>
                <subj-group subj-group-type="allowCommenting">
                  <subject>Comments</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia</article-title>
                <subtitle>A Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia</alt-title>
                <alt-title alt-title-type="running-head">Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Irwin</surname>
                    <given-names>Michael R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi210068aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi210068aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carrillo</surname>
                    <given-names>Carmen</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <degrees>MHS</degrees>
                  <xref rid="yoi210068aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sadeghi</surname>
                    <given-names>Nina</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref rid="yoi210068aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bjurstrom</surname>
                    <given-names>Martin F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi210068aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Breen</surname>
                    <given-names>Elizabeth C.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi210068aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi210068aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Olmstead</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi210068aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi210068aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="yoi210068aff1"><label>1</label>Cousins Center for Psychoneuroimmunology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (University of California, Los Angeles)</aff>
              <aff id="yoi210068aff2"><label>2</label>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> September 27, 2021.</p>
                <p content-type="published-online"><bold>Published Online:</bold> November 24, 2021. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamapsychiatry.2021.3422</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2021 Irwin MR et al. <italic toggle="yes">JAMA Psychiatry</italic>.</p>
                <corresp id="yoi210068cor1"><bold>Corresponding Author:</bold> Michael R. Irwin, MD, Cousins Center for Psychoneuroimmunology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Ste 3109, Los Angeles, CA 90095 (<email xlink:href="mirwin1@ucla.edu">mirwin1@ucla.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Irwin and Olmstead had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic toggle="yes">Concept and design:</italic> Irwin, Bjurstrom, Breen, Olmstead.</p>
                <p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Irwin, Carrillo, Sadeghi, Bjurstrom, Olmstead.</p>
                <p><italic toggle="yes">Drafting of the manuscript:</italic> Irwin, Sadeghi, Olmstead.</p>
                <p><italic toggle="yes">Critical revision of the manuscript for important intellectual content:</italic> Irwin, Carrillo, Bjurstrom, Breen, Olmstead.</p>
                <p><italic toggle="yes">Statistical analysis:</italic> Irwin, Carrillo, Bjurstrom, Olmstead.</p>
                <p><italic toggle="yes">Obtained funding:</italic> Irwin.</p>
                <p><italic toggle="yes">Administrative, technical, or material support:</italic> Irwin, Carrillo, Sadeghi, Bjurstrom, Breen.</p>
                <p><italic toggle="yes">Supervision:</italic> Irwin.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures</bold>: None reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> The study was funded by grant R01 AG026364 from the National Institute on Aging, National Institutes of Health, to the University of California, which partially supported the authors’ salaries.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2021-11-24T10:00">
                <day>24</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>79</volume>
              <issue>1</issue>
              <fpage>1</fpage>
              <lpage>9</lpage>
              <history>
                <date date-type="received">
                  <day>25</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2021 Irwin MR et al. <italic toggle="yes">JAMA Psychiatry</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamapsychiatry-e213422.pdf">jamapsychiatry-e213422.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archpsyc/fullarticle/10.1001/jamapsychiatry.2021.3422"/>
              <related-article related-article-type="commentary" ext-link-type="doi" id="YED210010" xlink:href="10.1001/jamapsychiatry.2021.3153"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-yoi210068-1">
                  <title>Question</title>
                  <p>Does treatment of insomnia prevent depression in community-dwelling adults 60 years or older without depression but with insomnia?</p>
                </sec>
                <sec id="ab-yoi210068-2">
                  <title>Findings</title>
                  <p>In this randomized clinical trial of 291 adults 60 years or older with insomnia disorder, 2 months of cognitive behavioral therapy for insomnia (CBT-I) resulted in a decreased likelihood of incident and recurrent depression during 36 months of follow-up compared with an active comparator control, sleep education therapy. Sustained insomnia remission in adults undergoing CBT-I resulted in a decreased likelihood of depression vs no insomnia remission in adults receiving sleep education therapy.</p>
                </sec>
                <sec id="ab-yoi210068-3">
                  <title>Meaning</title>
                  <p>Treatment of insomnia may be beneficial in the prevention of depression in older adults.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-yoi210068-4">
                  <title>Importance</title>
                  <p>Older adults with insomnia have a high risk of incident and recurrent depression. Depression prevention is urgently needed, and such efforts have been neglected for older adults.</p>
                </sec>
                <sec id="ab-yoi210068-5">
                  <title>Objective</title>
                  <p>To examine whether treatment of insomnia disorder with cognitive behavioral therapy for insomnia (CBT-I) compared with an active comparator condition, sleep education therapy (SET), prevents major depressive disorder in older adults.</p>
                </sec>
                <sec id="ab-yoi210068-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This assessor-blinded, parallel-group, single-site randomized clinical trial assessed a community-based sample of 431 people and enrolled 291 adults 60 years or older with insomnia disorder who had no major depression or major health events in past year. Study recruitment was performed from July 1, 2012, to April 30, 2015. The trial protocol was modified to extend follow-up from 24 to 36 months, with follow-up completion in July 2018. Data analysis was performed from March 1, 2019, to March 30, 2020.</p>
                </sec>
                <sec id="ab-yoi210068-7">
                  <title>Interventions</title>
                  <p>Participants were randomized to 2 months of CBT-I (n = 156) or SET (n = 135).</p>
                </sec>
                <sec id="ab-yoi210068-8">
                  <title>Main Outcomes and Measures</title>
                  <p>The primary outcome was time to incident major depressive disorder as diagnosed by interview and <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic> (Fifth Edition) criteria. Secondary outcome was sustained remission of insomnia disorder before depression event or duration of follow-up.</p>
                </sec>
                <sec id="ab-yoi210068-9">
                  <title>Results</title>
                  <p>Among 291 randomized participants (mean [SD] age, 70.1 [6.7] years; 168 [57.7%] female; 7 [2.4%] Asian, 32 [11.0%] Black, 3 [1.0%] Pacific Islander, 241 [82.8%] White, 6 [2.1%] multiracial, and 2 [0.7%] unknown), 156 were randomized to CBT-I and 135 to SET. A total of 140 participants (89.7%) completed CBT-I and 130 (96.3%) participants completed SET (χ<sup>2</sup> = 4.9, <italic toggle="yes">P</italic> = .03), with 114 (73.1%) completing 24 months of follow-up in the CBT-I group and 117 (86.7%) in the SET group (χ<sup>2</sup> = 8.4, <italic toggle="yes">P</italic> = .004). After protocol modification, 92 (59.0%) of the CBT-I participants and 86 (63.7%) of the SET participants agreed to extended follow-up (χ<sup>2</sup> = 0.7, <italic toggle="yes">P</italic> = .41), with 81 (51.9%) of the CBT-I participants and 77 (57.0%) of the SET group completing 36 months of follow-up (χ<sup>2</sup> = 0.8; <italic toggle="yes">P</italic> = .39). Incident or recurrent major depression occurred in 19 participants (12.2%) in the CBT-I group and in 35 participants (25.9%) in the SET group, with an overall benefit (hazard ratio, 0.51; 95%, CI 0.29-0.88; <italic toggle="yes">P</italic> = .02) consistent across subgroups. Remission of insomnia disorder continuously sustained before depression event or during follow-up was more likely in CBT-I participants (41 [26.3%]) compared with the SET participants (26 [19.3%], <italic toggle="yes">P</italic> = .03). Those in the CBT-I group with sustained remission of insomnia disorder had an 82.6% decreased likelihood of depression (hazard ratio, 0.17; 95%, CI 0.04-0.73; <italic toggle="yes">P</italic> = .02) compared with those in the SET group without sustained remission of insomnia disorder.</p>
                </sec>
                <sec id="ab-yoi210068-10">
                  <title>Conclusions and Relevance</title>
                  <p>The findings of this randomized clinical trial indicate that treatment of insomnia with CBT-I has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder. Community-level screening for insomnia concerns in older adults and wide delivery of CBT-I–based treatment for insomnia could substantially advance public health efforts to treat insomnia and prevent depression in this vulnerable older adult population.</p>
                </sec>
                <sec id="ab-yoi210068-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01641263" ext-link-type="uri">NCT01641263</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This randomized clinical trial of adults without depression but with insomnia assesses whether insomnia treatment can prevent depression.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-YOI210068">
              <title>Introduction</title>
              <p>Late-life depression (major depressive disorder in adults ≥60 years) has a 12-month prevalence that exceeds 10% in community-dwelling, older adults<sup><xref rid="yoi210068r1" ref-type="bibr">1</xref></sup> and is a significant risk factor for cognitive decline, disability, medical comorbidity, and all-cause mortality,<sup><xref rid="yoi210068r2" ref-type="bibr">2</xref>,<xref rid="yoi210068r3" ref-type="bibr">3</xref></sup> with suicide rates highest for older men.<sup><xref rid="yoi210068r4" ref-type="bibr">4</xref></sup> However, older adults with depression often do not receive diagnosis and treatment,<sup><xref rid="yoi210068r5" ref-type="bibr">5</xref></sup> and even with treatment, only approximately one-third achieve remission,<sup><xref rid="yoi210068r6" ref-type="bibr">6</xref></sup> with an estimated remaining disease burden of 60%.<sup><xref rid="yoi210068r7" ref-type="bibr">7</xref></sup> Effective depression prevention is urgently needed.<sup><xref rid="yoi210068r8" ref-type="bibr">8</xref></sup> However, such efforts have been neglected for community-dwelling, older adults, which is striking given that older adults account for nearly 20% of the population in the US, are most vulnerable to depression burden, and report the lowest use of mental health services.<sup><xref rid="yoi210068r9" ref-type="bibr">9</xref></sup></p>
              <p>Insomnia, occurring in nearly 50% of persons 60 years or older,<sup><xref rid="yoi210068r10" ref-type="bibr">10</xref></sup> contributes to a 2-fold greater risk of major depression.<sup><xref rid="yoi210068r11" ref-type="bibr">11</xref>,<xref rid="yoi210068r12" ref-type="bibr">12</xref></sup> Pharmacotherapy is often used to treat insomnia, although medication provides only temporary remediation and poses risk for daytime effects and dependency. Among the nonpharmacologic treatments for insomnia, a universal behavioral program is sleep education therapy (SET), which targets day-to-day behavioral and environmental factors that contribute to poor sleep.<sup><xref rid="yoi210068r13" ref-type="bibr">13</xref>,<xref rid="yoi210068r14" ref-type="bibr">14</xref></sup> Another nonpharmacologic treatment, cognitive behavioral therapy for insomnia (CBT-I), combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation; CBT-I is recommended as the first-line treatment for insomnia disorder.<sup><xref rid="yoi210068r15" ref-type="bibr">15</xref>,<xref rid="yoi210068r16" ref-type="bibr">16</xref>,<xref rid="yoi210068r17" ref-type="bibr">17</xref></sup></p>
              <p>In patients with residual or concurrent depression, CBT-I can improve insomnia symptoms but has only mixed results for depression outcomes.<sup><xref rid="yoi210068r18" ref-type="bibr">18</xref>,<xref rid="yoi210068r19" ref-type="bibr">19</xref>,<xref rid="yoi210068r20" ref-type="bibr">20</xref>,<xref rid="yoi210068r21" ref-type="bibr">21</xref>,<xref rid="yoi210068r22" ref-type="bibr">22</xref></sup> In adults, not older adults, with subsyndromal depressive symptoms and insomnia, 2 prevention trials<sup><xref rid="yoi210068r23" ref-type="bibr">23</xref>,<xref rid="yoi210068r24" ref-type="bibr">24</xref></sup> found that digitally based insomnia treatment programs reduced depressive symptoms in the short term, although this outcome might be viewed as treatment of subthreshold symptoms.<sup><xref rid="yoi210068r25" ref-type="bibr">25</xref></sup> Neither study<sup><xref rid="yoi210068r23" ref-type="bibr">23</xref>,<xref rid="yoi210068r24" ref-type="bibr">24</xref></sup> demonstrated prevention of major depression. A key uncertainty is whether depression can be selectively prevented,<sup><xref rid="yoi210068r26" ref-type="bibr">26</xref>,<xref rid="yoi210068r27" ref-type="bibr">27</xref>,<xref rid="yoi210068r28" ref-type="bibr">28</xref></sup> using evidence-informed, psychobehavioral treatments that target insomnia, and whether this benefit can be achieved in older adults without depression but with insomnia disorder.</p>
              <p>In this selective prevention trial,<sup><xref rid="yoi210068r26" ref-type="bibr">26</xref></sup> we present primary end point results during 36 months of follow-up in which we examined whether CBT-I compared with SET, an active comparator condition, would prevent incident or recurrent major depressive disorder, as defined by <italic toggle="yes">DSM-5</italic> criteria<sup><xref rid="yoi210068r29" ref-type="bibr">29</xref></sup> in community-dwelling, older adults with insomnia disorder and minimal depressive symptoms. Secondary analysis accounted for sustained remission of insomnia disorder before depression event or throughout follow-up.</p>
            </sec>
            <sec id="H1-2-YOI210068">
              <title>Methods</title>
              <sec id="H2-1-YOI210068">
                <title>Trial Design and Oversight</title>
                <p>Study recruitment was performed from July 1, 2012, to April 30, 2015. After screening of 431 people and enrollment of 60 participants, this assessor-blinded, single-site randomized clinical trial found that the incidence of depression was lower than estimated; the trial protocol was modified with follow-up extended from 24 to 36 months to achieve an adequate number of events for analysis, with follow-up completion in July 2018. Total trial enrollment was 291 participants. Data analysis was performed from March 1, 2019, to March 30, 2020. Participants provided written informed consent as approved by the UCLA (University of California, Los Angeles) Institutional Review Board; an additional, secondary written informed consent was required for entry into extended follow-up. All data were deidentified. Trial data monitoring and steering committees of the UCLA Clinical Translational Sciences Institute oversaw the study, which was undertaken according to the intention-to-treat principle. This study adhered to the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline.<sup><xref rid="yoi210068r30" ref-type="bibr">30</xref></sup> The trial protocol and statistical analysis plan are described in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p>
              </sec>
              <sec id="H2-2-YOI210068">
                <title>Participants</title>
                <p>A community sample of adults 60 years or older was identified using a database of all available telephone numbers and mailing addresses of households with at least 1 person 60 years or older who resided within 15 miles of UCLA, similar to sampling methods used in national surveys.<sup><xref rid="yoi210068r31" ref-type="bibr">31</xref>,<xref rid="yoi210068r32" ref-type="bibr">32</xref></sup> Screening eligibility assessed general sleep disturbance (ie, Pittsburgh Sleep Quality Index score &gt;5)<sup><xref rid="yoi210068r33" ref-type="bibr">33</xref></sup> and depression (ie, 10-item Center for Epidemiologic Studies–Depression score &lt;4).<sup><xref rid="yoi210068r34" ref-type="bibr">34</xref></sup> Interviews confirmed the following inclusion criteria: insomnia disorder by <italic toggle="yes">DSM-IV</italic> and absence of <italic toggle="yes">DSM-IV</italic> or <italic toggle="yes">DSM-5</italic> major depression within the last 12 months (<xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 1</xref>). Self-reported race and ethnicity data informed generalizability and satisfied National Institutes of Health requirements.</p>
              </sec>
              <sec id="H2-3-YOI210068">
                <title>Trial Procedures</title>
                <p>Participants were randomly allocated in a 1:1 ratio to CBT-I or SET. Randomization was performed using computer-generated random number sequence, with block sizes from 5 to 10 participants, by an independent researcher (R.O.). Allocation concealment used sequentially numbered, opaque, sealed envelopes, with treatment allocation after baseline. Assessors were blind to allocation.</p>
                <p>The CBT-I and SET interventions were delivered by a trained psychologist (CBT-I) or trained public health educator (SET) in weekly 120-minute group sessions for 2 months, consistent with group format and duration of most CBT-I trials.<sup><xref rid="yoi210068r35" ref-type="bibr">35</xref>,<xref rid="yoi210068r36" ref-type="bibr">36</xref></sup> The CBT-I contained 5 components: cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation. Together these components target sleep-related physiologic and cognitive arousal to reestablish restorative sleep function.<sup><xref rid="yoi210068r14" ref-type="bibr">14</xref></sup> Clinician-delivered CBT-I yields greater and more durable effects, with higher rates of adherence and retention, than digital CBT-I.<sup><xref rid="yoi210068r36" ref-type="bibr">36</xref>,<xref rid="yoi210068r37" ref-type="bibr">37</xref>,<xref rid="yoi210068r38" ref-type="bibr">38</xref></sup> SET contained 5 components: sleep hygiene, sleep biology, characteristics of healthy sleep, stress biology, and impact on sleep. SET is an active comparator condition that improves insomnia symptoms but is less robust and durable than CBT-I.<sup><xref rid="yoi210068r13" ref-type="bibr">13</xref>,<xref rid="yoi210068r14" ref-type="bibr">14</xref>,<xref rid="yoi210068r39" ref-type="bibr">39</xref></sup> Instructors recorded attendance, and participants rated treatment expectancy and acceptability and adherence at the end of treatment. Independent therapists performed therapist competency checks before treatment delivery and rated treatment fidelity.</p>
              </sec>
              <sec id="H2-4-YOI210068">
                <title>Outcomes</title>
                <p>The primary outcome was time to incident or recurrent major depressive disorder as diagnosed by the Structured Clinical Interview of the <italic toggle="yes">DSM-5</italic> every 6 months during 36 months of follow-up,<sup><xref rid="yoi210068r29" ref-type="bibr">29</xref></sup> as assigned in a consensus meeting. Between assessments, a monthly Patient Health Questionnaire 9 (PHQ-9) administered via an automated telephone response system screened for depressive symptoms. Score range for the PHQ-9 is from 0 to 27, with higher scores indicating more severe depressive symptoms. If the PHQ-9 score was 10 or higher, the participant underwent an additional Structured Clinical Interview. The secondary outcome was sustained remission of insomnia disorder by <italic toggle="yes">DSM-5</italic> criteria, as defined by absence of insomnia disorder at each follow-up assessment before a depression event or throughout follow-up.</p>
              </sec>
              <sec id="H2-5-YOI210068">
                <title>Adverse Events Monitored</title>
                <p>Meta-analytic data indicate that insomnia is associated with incident depression (odds ratio, 2.1; 95% CI, 1.86-2.38). Annual percentage incidence of depression is 13.1 in those with insomnia (n = 797) and 4.0 in those without insomnia (n = 6919)<sup><xref rid="yoi210068r11" ref-type="bibr">11</xref></sup>; global depression incidence is estimated at 3.0 (95% CI, 2.4-3.8; n = 35 212).<sup><xref rid="yoi210068r40" ref-type="bibr">40</xref></sup> The study was powered to detect a hazard ratio (HR) of 0.50 between CBT-I and SET at 24 months for the primary outcome, with 80% power, a 2-sided 5% α level, and assuming a small clustering effect (intraclass correlation = 0.01), producing a target sample size of 250 (125 per group). The sample size was increased by 10% to consider dropout. After enrollment and follow-up of 60 participants, the observed annual incidence of depression was 9.6, and the protocol was modified by follow-up extension to 36 months to achieve an adequate number of events for analysis and statistical power at greater than 80%. For the secondary outcome, differences in remission rate of insomnia disorder between CBT-I and SET in older adults<sup><xref rid="yoi210068r39" ref-type="bibr">39</xref></sup> provided an estimated power of greater than 90% at a 2-sided α level of 5%.</p>
              </sec>
              <sec id="H2-6-YOI210068">
                <title>Statistical Analysis</title>
                <p>The primary outcome, incident <italic toggle="yes">DSM-5</italic> major depression, was analyzed with time-to-event methods using a Cox proportional hazards regression model. The scaled Schoenfeld residuals test assessed the proportional hazards assumption. The primary model did not control for covariates, providing an unconditional (generalizable) estimate of risk of incident and recurrent depression.<sup><xref rid="yoi210068r30" ref-type="bibr">30</xref></sup></p>
                <p>All participants met <italic toggle="yes">DSM-IV</italic> insomnia disorder criteria. After study enrollment began in 2012, the duration criteria for insomnia disorder were revised by <italic toggle="yes">DSM-5</italic>; hence, exploratory analysis of the primary outcome was conducted in the subsample who also met <italic toggle="yes">DSM-5</italic> insomnia disorder.<sup><xref rid="yoi210068r29" ref-type="bibr">29</xref></sup> Additional sensitivity analyses estimated the consistency of treatment effect across subgroups. The secondary outcome, remission of insomnia disorder, was evaluated after treatment and continuously sustained before depression event or duration of follow-up using adjusted mixed regression models. This definition of sustained remission of insomnia disorder modeled whether insomnia remission was temporally ordered before a depression event.</p>
                <p>A predefined analysis of the primary outcome was performed in which treatment groups were stratified by sustained remission of insomnia disorder as defined above; covariate-adjusted HRs for stratified groups were reported using SET without sustained remission of insomnia disorder as reference. An exploratory analysis evaluated HRs for incident depression in the total sample as a function of sustained remission of insomnia disorder (eResults in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                <p>Exploratory analyses examined sample characteristics by treatment group as a function of discontinuation; baseline characteristics did not differ in relation to discontinuation (eResults and eTables 1-3 in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). To explore effects of missing data on the primary outcome,<sup><xref rid="yoi210068r41" ref-type="bibr">41</xref></sup> sensitivity analyses iteratively modeled incident depression after last observation (ie, for those who discontinued) using multiple (i = 100) imputed data sets of a Pareto distribution based on observed and range of annual incidence of depression in SET (8.6 events per 100 person-years; 95% CI, 3.8-13.3 events per 100 person-years). For the secondary outcome, complete data sets were generated using an iterative Markov chain Monte Carlo method. Finally, exploratory analyses examined the trajectory of change in depressive symptoms and suicidal ideation (eResults in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). SPSS software, version 27 (IBM Inc) was used for statistical analysis. A 2-sided <italic toggle="yes">P</italic> &lt; .05 was considered statistically significant.</p>
              </sec>
            </sec>
            <sec id="H1-3-YOI210068">
              <title>Results</title>
              <sec id="H2-7-YOI210068">
                <title>Participants and Treatment</title>
                <p> Among 291 randomized participants (mean [SD] age, 70.1 [6.7] years; 168 [57.7%] female; 7 [2.4%] Asian, 32 [11.0%] Black, 3 [1.0%] Pacific Islander, 241 [82.8%] White 6 [2.1%] multiracial, and 2 [0.7%] of unknown race and ethnicity), 156 were randomized to CBT-I and 135 to SET (<xref rid="yoi210068f1" ref-type="fig">Figure 1</xref>; eResults in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). Groups had balanced baseline characteristics (<xref rid="yoi210068t1" ref-type="table">Table</xref>). Among the 123 with a history of depression, 116 (94.3%) reported depression more than 2 years earlier. Depressive symptom severity was in minimal range.</p>
                <fig position="float" id="yoi210068f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Patient Flowchart</title>
                    <p>Details regarding screening, eligibility assessment, treatment delivery, and follow-up evaluation are given in the Methods and the trial protocol (<xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 1</xref>). BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); CBT-I, cognitive behavioral therapy for insomnia; and SET, sleep education therapy.</p>
                  </caption>
                  <graphic xlink:href="jamapsychiatry-e213422-g001" position="float"/>
                </fig>
                <table-wrap position="float" id="yoi210068t1">
                  <label>Table. </label>
                  <caption>
                    <title>Characteristics of Participants by Treatment Group<xref rid="yoi210068t1n1" ref-type="table-fn"><sup>a</sup></xref></title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="60.99%" span="1"/>
                    <col width="18.81%" span="1"/>
                    <col width="20.2%" span="1"/>
                    <thead>
                      <tr>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">CBT-I (n = 156)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">SET (n = 135)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">70.2 (7.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">69.9 (6.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">86 (55.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">82 (60.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">70 (44.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 (39.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (1.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (3.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (10.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (11.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pacific Islander</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (1.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">130 (83.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">111 (82.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Multiracial</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (3.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic or Latino</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (7.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (3.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic or non-Latino</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">142 (91.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">130 (96.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Marital status</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Married or partnered</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">72 (46.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">64 (47.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Income, mean (SD), $ in thousands</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">85.6 (49.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">78.7 (47.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Full-time employment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">49 (31.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">49 (36.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Educational level, mean (SD), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16.9 (2.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16.4 (2.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27.1 (4.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26.2 (4.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Charlson Comorbidity Index, mean (SD)<xref rid="yoi210068t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.8 (1.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sleep disturbance</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">DSM-5</italic> insomnia diagnosis</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">127 (81.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">111 (82.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Duration of insomnia, mean (SD), mo</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17.7 (25.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20.9 (27.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Athens Insomnia Score, mean (SD)<xref rid="yoi210068t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.4 (3.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.5 (3.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Use of hypnotic medications</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (21.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (17.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Depression</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> History of depression</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58 (37.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65 (48.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Use of antidepressants</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25 (16.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20 (14.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> PHQ-8 score<xref rid="yoi210068t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.4 (2.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.0 (3.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">History of other psychiatric comorbidity</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Generalized anxiety disorder</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17 (10.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (14.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol use disorder</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (6.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (9.6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CBT-I, Cognitive Behavioral Therapy for Insomnia; PHQ-8, Patient Health Questionnaire 8; SET, Sleep Education Therapy.</p>
                    <fn id="yoi210068t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Data are presented as number (percentage) unless otherwise indicated. To be eligible for the study, all participants fulfilled <italic toggle="yes">International Classification for Sleep Disorder, Second Edition</italic> and <italic toggle="yes">DSM-IV</italic> criteria for insomnia; number and percentage who also fulfilled <italic toggle="yes">DSM-5</italic> criteria for insomnia disorder are given. After study onset, diagnostic criteria for <italic toggle="yes">DSM-IV</italic> insomnia disorder were revised by <italic toggle="yes">DSM-5</italic> to include criteria for frequency (sleep difficulties ≥3 times per week) and duration (≥3 months). Race and ethnicity were reported by the participants.</p>
                    </fn>
                    <fn id="yoi210068t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>The Charlson Comorbidity Index includes 17 categories of comorbidity, each with an assigned score of 1 to 6, depending on the risk of death associated with the condition; maximum score is 29.</p>
                    </fn>
                    <fn id="yoi210068t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>The Athens Insomnia Score rates severity of sleep disturbance according to the <italic toggle="yes">International Classification for Sleep Disorder, Second Edition</italic> for insomnia diagnosis. Scores range from 0 to 24 for the 8-item version, and a score of 6 or higher has optimal sensitivity and specificity for the diagnosis of insomnia.</p>
                    </fn>
                    <fn id="yoi210068t1n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Severity of depressive symptoms at baseline was evaluated with the PHQ-8 (equivalent to Patient Health Questionnaire 9 without the insomnia item; all participants had insomnia).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-8-YOI210068">
                <title>Adherence and Follow-up Retention</title>
                <p>Treatment expectancy, acceptability, adherence, attendance, and fidelity were similar (eResults in the <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). A total of 140 participants (89.7%) completed CBT-I and 130 (96.3%) participants completed SET (χ<sup>2</sup> = 4.9, <italic toggle="yes">P</italic> = .03), with 114 (73.1%) completing 24 months of follow-up in the CBT-I group and 117 (86.7%) in the SET group (χ<sup>2</sup> = 8.4, <italic toggle="yes">P</italic> = .004). After protocol modification, 92 (59.0%) of the CBT-I participants and 86 (63.7%) of the SET participants agreed to extended follow-up (χ<sup>2</sup> = 0.7, <italic toggle="yes">P</italic> = .41), with 81 (51.9%) of the CBT-I group and 77 (57.0%) of the SET group completing 36 months of follow-up (χ<sup>2</sup> = 0.8; <italic toggle="yes">P</italic> = .39) (eTable 1 in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). Reasons for discontinuation did not reveal systematic differences (<xref rid="yoi210068f1" ref-type="fig">Figure 1</xref>). Sample characteristics by treatment group as a function of discontinuation were similar at treatment completion, 24-month follow-up, and entry into extended follow-up (eTables 2-4 in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). Discontinuation at treatment completion or 24-month follow-up was not related to treatment expectancy (eResults in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). Among those who declined extended follow-up, most enrolled before protocol modification (CBT-I, 21 [95.5%]; SET, 29 [93.5%]). Median duration of follow-up was 36 months (IQR, 12-36 months) in CBT-I and 36 months (IQR, 24-36 months) in SET (median test <italic toggle="yes">P</italic> = .46).</p>
              </sec>
              <sec id="H2-9-YOI210068">
                <title>Primary Outcome</title>
                <p>The primary outcome, incident or recurrent major depression (ie, depression), occurred in 19 participants (12.2%) in the CBT-I group (4.1 events per 100 person-years; 95% CI, 1.0-7.2 events per 100 person-years; 4.1% annual incidence) and in 35 participants (25.9%) in the SET group (8.6 events per 100 person-years; 95% CI, 3.8-13.3 events per 100 person-years; 8.6% annual incidence; χ<sup>2</sup> = 9.05; <italic toggle="yes">P</italic> = .003) (<xref rid="yoi210068f2" ref-type="fig">Figure 2</xref>). The HR for depression in the CBT-I group, compared with the SET group, was 0.51 (95% CI, 0.29-0.88; <italic toggle="yes">P</italic> = .02). The number needed to treat to prevent incident or recurrent depression was 7.3 (95% CI, 4.4-21.1). The test for the proportional hazards assumption with Schoenfeld residuals gave a <italic toggle="yes">P</italic> = .86, indicating no violation. Predefined analyses adjusted for sex, educational level, income, comorbidity, and history of depression, all known to contribute to depression risk<sup><xref rid="yoi210068r42" ref-type="bibr">42</xref></sup>; the adjusted HR for depression in the CBT-I group, compared with the SET group, was 0.45 (95% CI, 0.23-0.86; <italic toggle="yes">P</italic> = .02) (eTable 5 in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). Exploratory analyses adjusted for baseline severity of depressive symptoms without the insomnia item (PHQ-9 without the insomnia item, or PHQ-8) and use of antidepressant and sedative hypnotic medications; the adjusted HR for depression in CBT-I, compared with SET, was 0.41 (95% CI, 0.20-0.85; <italic toggle="yes">P</italic> = .02), a nearly 60% reduction in likelihood of depression. Other variables, such as treatment adherence, attendance, expectancy, acceptability, and duration of insomnia, were not related to depression events.</p>
                <fig position="float" id="yoi210068f2" fig-type="figure">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Time to Incident or Recurrent Depression Event by Treatment Group</title>
                    <p>Older adults without depression but with insomnia were randomized to receive cognitive behavioral therapy for insomnia (CBT-I) or sleep education therapy (SET).</p>
                  </caption>
                  <graphic xlink:href="jamapsychiatry-e213422-g002" position="float"/>
                </fig>
                <p>All participants fulfilled <italic toggle="yes">DSM-IV</italic> insomnia disorder. For the subsample who also fulfilled <italic toggle="yes">DSM-5</italic> insomnia disorder, results were similar (<xref rid="yoi210068f3" ref-type="fig">Figure 3</xref>; eFigure 1 in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>). Other exploratory subgroup analyses found a survival benefit in the CBT-I group that was generally consistent with the overall sample; some subgroups (eg, races other than White) had greater variability, possibly because of small sample sizes.</p>
                <fig position="float" id="yoi210068f3" fig-type="figure">
                  <label>Figure 3. </label>
                  <caption>
                    <title>Risk of Incident or Recurrent Major Depression (Primary Outcome) in Subgroups</title>
                    <p>Percentages may not total 100 because of rounding. Race was reported by the participant. Because 241 individuals (82.8%) in the sample were White, sizes for other ethnic groups (ie, 7 [2.4%] Asian, 32 [11.0%] Black, 3 [1.0%] Pacific Islander, 6 [2.1%] multiracial) were too small for statistical comparisons. Comorbidity was evaluated by the Charlson Comorbidity Index, with higher scores indicating greater comorbidity disability. All participants fulfilled <italic toggle="yes">International Classification for Sleep Disorder, Second Edition</italic> and <italic toggle="yes">DSM-IV </italic>criteria for insomnia; a subsample met the duration criteria for insomnia disorder as specified by <italic toggle="yes">DSM-5</italic>.<sup><xref rid="yoi210068r29" ref-type="bibr">29</xref></sup> The no-effect point is 1 on the x-axis; the dashed vertical line indicates the hazard ratio (HR) of 0.51 for the total sample. The HRs were estimated on the basis of a unadjusted Cox proportional hazards regression model. The HRs for some subgroups had wide 95% CIs owing to the small number of patients. CBT-I indicates cognitive behavioral therapy for insomnia; SET, sleep education therapy.</p>
                  </caption>
                  <graphic xlink:href="jamapsychiatry-e213422-g003" position="float"/>
                </fig>
                <p>Sensitivity analysis examined the influence of discontinuation on the primary outcome. For those who discontinued treatment, depression event after last observation was modeled using observed annual incidence of depression of SET (8.6 events per 100 person-years); the adjusted HR for incident depression in the CBT-I group, compared with the SET group, was 0.53 (95% CI, 0.29-0.99; <italic toggle="yes">P</italic> = .05), with similar results by iteratively modeling across the 95% CI.</p>
              </sec>
              <sec id="H2-10-YOI210068">
                <title>Secondary Outcome</title>
                <p>The proportion of participants who achieved remission of insomnia disorder after treatment was greater in the CBT-I group (71 [50.7%]) compared with the SET group (49 [37.7%]; adjusted β = 0.52; 95% CI, 0.10-0.93; <italic toggle="yes">P</italic> = .02); similar results were found for sustained remission of insomnia disorder (ie, insomnia remission) in the CBT-I group (41 [26.3%]) compared with the SET group (26 [19.3%]; adjusted β = 0.56; 95% CI, 0.07-1.04; <italic toggle="yes">P</italic> = .03). Sensitivity analysis using imputed data yielded similar results after treatment (adjusted β = 0.49; 95% CI, 0.07-0.91; <italic toggle="yes">P</italic> = .03) and for sustained remission of insomnia disorder (adjusted β = 0.47; 95% CI, −0.11 to 1.05; <italic toggle="yes">P</italic> = .09). Rate of exposure to sedative hypnotic medications decreased more in the CBT-I group (−0.024) compared with the SET group (−0.013; <italic toggle="yes">F</italic><sub>1,1468</sub> = 6.25; <italic toggle="yes">P</italic> = .01) but not for antidepressant medications (<italic toggle="yes">F</italic><sub>1,1468</sub> = 0.006; <italic toggle="yes">P</italic> = .94).</p>
                <p>Given the superiority of CBT-I over SET on remission of insomnia disorder, predefined analysis compared treatment groups as a function of sustained remission of insomnia disorder. The primary outcome of incident or recurrent major depression occurred in 2 participants (4.9%) in the CBT-I group with insomnia remission, 17 participants (14.8%) in the CBT-I group without insomnia remission, 5 participants (19.2%) in the SET group with insomnia remission, and 30 participants (27.5%) in the SET group with no insomnia remission. The adjusted HR for depression was 0.17 (95% CI, 0.04-0.73; <italic toggle="yes">P</italic> = .02) in the CBT-I group with insomnia remission, 0.59 (95% CI, 0.33-1.07; <italic toggle="yes">P</italic> = .08) in the CBT-I group with no insomnia remission, and 0.68 (95% CI, 0.26-1.75; <italic toggle="yes">P</italic> = .42) in the SET group with insomnia remission compared with the SET group with no insomnia remission (<xref rid="yoi210068f4" ref-type="fig">Figure 4</xref>). Exploratory analyses in the total sample found a survival benefit of sustained remission of insomnia disorder and of percentage duration of remission of insomnia during follow-up (eTable 6 and eFigures 2 and 3 in <xref rid="note-YOI210068-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                <fig position="float" id="yoi210068f4" fig-type="figure">
                  <label>Figure 4. </label>
                  <caption>
                    <title>Time to Incident or Recurrent Depression Event by Treatment Group, Stratified by Sustained Remission of Insomnia Disorder</title>
                    <p>Older adults without depression were randomized to receive cognitive behavioral therapy for insomnia (CBT-I) or sleep education therapy (SET). Analyses stratified treatment group according to sustained remission of insomnia disorder as defined by absence of insomnia disorder at each follow-up assessment before depression event or during follow-up.</p>
                  </caption>
                  <graphic xlink:href="jamapsychiatry-e213422-g004" position="float"/>
                </fig>
              </sec>
              <sec id="H2-11-YOI210068">
                <title>Adverse Events</title>
                <p>No adverse events were observed during treatment. During follow-up, serious events were identified in the CBT-I group (4 illnesses and 1 death) and SET group (1 death); none were attributed to trial.</p>
              </sec>
            </sec>
            <sec id="H1-4-YOI210068">
              <title>Discussion</title>
              <p>In older adults with insomnia disorder but without depression, CBT-I administration provided significant benefit to prevent incident and recurrent major depressive disorder, with evidence of treatment separation beginning at 6 months and widening during follow-up. This overall benefit was generally consistent across participant subgroups. In addition, CBT-I provided benefit in sustained remission of insomnia disorder, and durable treatment of insomnia magnified the benefit of CBT-I to prevent incident and recurrent major depression.</p>
              <p>Treatment with CBT-I yielded an annual incidence of depression at 4.1%, similar to the population rate<sup><xref rid="yoi210068r11" ref-type="bibr">11</xref>,<xref rid="yoi210068r40" ref-type="bibr">40</xref></sup> and half the rate in SET at 8.6%, consistent with a 2-fold greater risk of depression in those with insomnia.<sup><xref rid="yoi210068r11" ref-type="bibr">11</xref></sup> The efficacy of CBT-I to prevent depression by more than 50% with a number needed to treat of 7 contrasts with meta-analytic findings of an approximately 20% reduction in depression and number needed to treat of 20,<sup><xref rid="yoi210068r28" ref-type="bibr">28</xref>,<xref rid="yoi210068r43" ref-type="bibr">43</xref>,<xref rid="yoi210068r44" ref-type="bibr">44</xref></sup> possibly because most prior trials<sup><xref rid="yoi210068r28" ref-type="bibr">28</xref>,<xref rid="yoi210068r44" ref-type="bibr">44</xref>,<xref rid="yoi210068r45" ref-type="bibr">45</xref></sup> assessed prevention using different types of omnibus therapies, whereas this selective prevention trial targeted insomnia disorder, a robust risk factor for depression, and used evidence-based CBT-I, known to be an effective and durable treatment of insomnia. Given that most prior trials<sup><xref rid="yoi210068r28" ref-type="bibr">28</xref>,<xref rid="yoi210068r45" ref-type="bibr">45</xref></sup> did not use an active comparator control as done in this current trial, the relatively large survival benefit of CBT-I is striking.</p>
              <p>Among the small number of prevention trials, almost none have examined the mechanisms that contribute to their effectiveness.<sup><xref rid="yoi210068r46" ref-type="bibr">46</xref>,<xref rid="yoi210068r47" ref-type="bibr">47</xref></sup> Given that inflammatory activation induces depressive symptoms<sup><xref rid="yoi210068r48" ref-type="bibr">48</xref>,<xref rid="yoi210068r49" ref-type="bibr">49</xref>,<xref rid="yoi210068r50" ref-type="bibr">50</xref>,<xref rid="yoi210068r51" ref-type="bibr">51</xref>,<xref rid="yoi210068r52" ref-type="bibr">52</xref></sup> and durable remission of insomnia reverses genomic, cellular, and systemic markers of inflammation,<sup><xref rid="yoi210068r53" ref-type="bibr">53</xref>,<xref rid="yoi210068r54" ref-type="bibr">54</xref></sup> secondary analysis will examine whether mitigation of inflammation contributes to prevention of depression.</p>
              <p>This selective prevention trial is one of the largest, with the longest follow-up,<sup><xref rid="yoi210068r28" ref-type="bibr">28</xref></sup> to answer an important clinical question of high relevance to geriatric psychiatry and older adults at risk for incident and recurrent depression. Internal validity was established for CBT-I vs SET with similar treatment expectancy, acceptability, and adherence; monthly monitoring; retention; and assessor blinding of diagnostic outcomes. External validity was maximized by long-term follow-up, with the annual incidence of depression in SET vs CBT-I similar to population estimates for those with and without insomnia, respectively.<sup><xref rid="yoi210068r11" ref-type="bibr">11</xref>,<xref rid="yoi210068r40" ref-type="bibr">40</xref></sup> Dissemination potential was optimized by cost-effective delivery of CBT-I in group format; telemedicine clinician delivery of CBT-I is noninferior to in-person CBT-I,<sup><xref rid="yoi210068r48" ref-type="bibr">48</xref></sup> which would expand dissemination to remote communities.<sup><xref rid="yoi210068r49" ref-type="bibr">49</xref></sup> Remission of insomnia disorder and prevention of depression were achieved with minimal patient burden (ie, 16 hours of treatment exposure and no booster sessions). Finally, because insomnia is associated with suicidal ideation<sup><xref rid="yoi210068r50" ref-type="bibr">50</xref></sup> and dementia,<sup><xref rid="yoi210068r51" ref-type="bibr">51</xref></sup> CBT-I may have added value in reducing the risk of suicide<sup><xref rid="yoi210068r50" ref-type="bibr">50</xref></sup> or cognitive decline.</p>
              <sec id="H2-12-YOI210068">
                <title>Limitations</title>
                <p>Although there was a differential rate of discontinuation in the first 24 months after treatment, this finding was not related to treatment expectancy or sample characteristics, such as depressive symptoms, which can alter adherence to CBT-I.<sup><xref rid="yoi210068r21" ref-type="bibr">21</xref></sup> When the annual incidence of depression for all who discontinued treatment was modeled using the observed value for SET, the survival benefit of CBT-I was maintained. Given that a disproportionate burden of risk of insomnia and depression is carried by females and those who are of races other than White and/or have psychiatric and medical comorbidity,<sup><xref rid="yoi210068r52" ref-type="bibr">52</xref>,<xref rid="yoi210068r53" ref-type="bibr">53</xref></sup> external validity in these subgroups requires further research. After treatment, CBT-I resulted in a 50.7% insomnia remission rate, which is comparable to other CBT-I studies,<sup><xref rid="yoi210068r14" ref-type="bibr">14</xref>,<xref rid="yoi210068r54" ref-type="bibr">54</xref>,<xref rid="yoi210068r55" ref-type="bibr">55</xref></sup> and a 26.3% achieved sustained remission rate during 3 years. Nevertheless, the survival benefit of CBT-I was significant in those with and without sustained insomnia remission. Compared with digital CBT-I, clinician delivery may limit dissemination, although digital CBT-I has smaller effects on insomnia outcomes,<sup><xref rid="yoi210068r36" ref-type="bibr">36</xref>,<xref rid="yoi210068r38" ref-type="bibr">38</xref></sup> higher rates of attrition, and lower durability, which may together reduce efficacy<sup><xref rid="yoi210068r56" ref-type="bibr">56</xref>,<xref rid="yoi210068r57" ref-type="bibr">57</xref></sup> and depression prevention.<sup><xref rid="yoi210068r23" ref-type="bibr">23</xref></sup></p>
              </sec>
            </sec>
            <sec id="H1-5-YOI210068">
              <title>Conclusions</title>
              <p>In this trial of older adults without depression but with insomnia disorder, delivery of CBT-I prevented incident and recurrent major depressive disorder by more than 50% compared with SET, an active comparator. Community-level screening for insomnia concerns in older adults and wide delivery of CBT-I–based treatment for insomnia could substantially advance public health efforts to treat insomnia and prevent depression in this vulnerable older adult population. These data support further efforts to prevent depression by targeting risk factors such as insomnia disorder with the potential to maximize efficacy of depression prevention.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-YOI210068">
              <title>References</title>
              <ref id="yoi210068r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Andreas</surname><given-names>S</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>H</given-names></string-name>, <string-name><surname>Volkert</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence of mental disorders in elderly people: the European MentDis_ICF65+ study</article-title>. <source>Br J Psychiatry</source>. <year>2017</year>;<volume>210</volume>(<issue>2</issue>):<fpage>125</fpage>-<lpage>131</lpage>. doi:<pub-id pub-id-type="doi">10.1192/bjp.bp.115.180463</pub-id><?supplied-pmid 27609811?><pub-id pub-id-type="pmid">27609811</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Taylor</surname><given-names>WD</given-names></string-name></person-group>. <article-title>Clinical practice: depression in the elderly</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>(<issue>13</issue>):<fpage>1228</fpage>-<lpage>1236</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMcp1402180</pub-id><?supplied-pmid 25251617?><pub-id pub-id-type="pmid">25251617</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cuijpers</surname><given-names>P</given-names></string-name>, <string-name><surname>Vogelzangs</surname><given-names>N</given-names></string-name>, <string-name><surname>Twisk</surname><given-names>J</given-names></string-name>, <string-name><surname>Kleiboer</surname><given-names>A</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Penninx</surname><given-names>BW</given-names></string-name></person-group>. <article-title>Differential mortality rates in major and subthreshold depression: meta-analysis of studies that measured both</article-title>. <source>Br J Psychiatry</source>. <year>2013</year>;<volume>202</volume>(<issue>1</issue>):<fpage>22</fpage>-<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1192/bjp.bp.112.112169</pub-id><?supplied-pmid 23284149?><pub-id pub-id-type="pmid">23284149</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r4">
                <label>4</label>
                <mixed-citation publication-type="book"><person-group><string-name><surname>Eden</surname><given-names>J</given-names></string-name>, <string-name><surname>Maslow</surname><given-names>K</given-names></string-name>, <string-name><surname>Le</surname><given-names>M</given-names></string-name>, <string-name><surname>Blazer</surname><given-names>D</given-names></string-name>; <collab>Committee on Mental Health Workforce for Geriatric Populations</collab></person-group>. <source>The Mental Health and Substance Use Workforce for Older Adults: In Whose Hands?</source><publisher-name>National Academies Press, Institute of Medicine</publisher-name>; <year>2012</year>.</mixed-citation>
              </ref>
              <ref id="yoi210068r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Alexopoulos</surname><given-names>GS</given-names></string-name></person-group>. <article-title>Depression in the elderly</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>365</volume>(<issue>9475</issue>):<fpage>1961</fpage>-<lpage>1970</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(05)66665-2</pub-id><?supplied-pmid 15936426?><pub-id pub-id-type="pmid">15936426</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Roose</surname><given-names>SP</given-names></string-name>, <string-name><surname>Schatzberg</surname><given-names>AF</given-names></string-name></person-group>. <article-title>The efficacy of antidepressants in the treatment of late-life depression</article-title>. <source>J Clin Psychopharmacol</source>. <year>2005</year>;<volume>25</volume>(<issue>4</issue>)(<supplement>suppl 1</supplement>):<fpage>S1</fpage>-<lpage>S7</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.jcp.0000162807.84570.6b</pub-id><?supplied-pmid 16027554?><pub-id pub-id-type="pmid">16027554</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Andrews</surname><given-names>G</given-names></string-name>, <string-name><surname>Issakidis</surname><given-names>C</given-names></string-name>, <string-name><surname>Sanderson</surname><given-names>K</given-names></string-name>, <string-name><surname>Corry</surname><given-names>J</given-names></string-name>, <string-name><surname>Lapsley</surname><given-names>H</given-names></string-name></person-group>. <article-title>Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders</article-title>. <source>Br J Psychiatry</source>. <year>2004</year>;<volume>184</volume>:<fpage>526</fpage>-<lpage>533</lpage>. doi:<pub-id pub-id-type="doi">10.1192/bjp.184.6.526</pub-id><?supplied-pmid 15172947?><pub-id pub-id-type="pmid">15172947</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hoare</surname><given-names>E</given-names></string-name>, <string-name><surname>Callaly</surname><given-names>E</given-names></string-name>, <string-name><surname>Berk</surname><given-names>M</given-names></string-name></person-group>. <article-title>Can depression be prevented? If so, how?</article-title><source>JAMA Psychiatry</source>. <year>2020</year>;<volume>77</volume>(<issue>11</issue>):<fpage>1095</fpage>-<lpage>1096</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.1273</pub-id><?supplied-pmid 32579156?><pub-id pub-id-type="pmid">32579156</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Taylor</surname><given-names>WD</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>CF</given-names><suffix>III</suffix></string-name></person-group>. <article-title>Psychiatry’s obligation to treat and mitigate the rising burden of age-related mental disorders</article-title>. <source>JAMA Psychiatry</source>. <year>2020</year>;<volume>77</volume>(<issue>1</issue>):<fpage>5</fpage>-<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.2111</pub-id><?supplied-pmid 31461128?><pub-id pub-id-type="pmid">31461128</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Foley</surname><given-names>D</given-names></string-name>, <string-name><surname>Ancoli-Israel</surname><given-names>S</given-names></string-name>, <string-name><surname>Britz</surname><given-names>P</given-names></string-name>, <string-name><surname>Walsh</surname><given-names>J</given-names></string-name></person-group>. <article-title>Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey</article-title>. <source>J Psychosom Res</source>. <year>2004</year>;<volume>56</volume>(<issue>5</issue>):<fpage>497</fpage>-<lpage>502</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpsychores.2004.02.010</pub-id><?supplied-pmid 15172205?><pub-id pub-id-type="pmid">15172205</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Baglioni</surname><given-names>C</given-names></string-name>, <string-name><surname>Battagliese</surname><given-names>G</given-names></string-name>, <string-name><surname>Feige</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies</article-title>. <source>J Affect Disord</source>. <year>2011</year>;<volume>135</volume>(<issue>1-3</issue>):<fpage>10</fpage>-<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jad.2011.01.011</pub-id><?supplied-pmid 21300408?><pub-id pub-id-type="pmid">21300408</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cho</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Lavretsky</surname><given-names>H</given-names></string-name>, <string-name><surname>Olmstead</surname><given-names>R</given-names></string-name>, <string-name><surname>Levin</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Oxman</surname><given-names>MN</given-names></string-name>, <string-name><surname>Irwin</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study</article-title>. <source>Am J Psychiatry</source>. <year>2008</year>;<volume>165</volume>(<issue>12</issue>):<fpage>1543</fpage>-<lpage>1550</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07121882</pub-id><?supplied-pmid 18765482?><pub-id pub-id-type="pmid">18765482</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Montgomery</surname><given-names>P</given-names></string-name>, <string-name><surname>Dennis</surname><given-names>J</given-names></string-name></person-group>. <article-title>Cognitive behavioural interventions for sleep problems in adults aged 60+</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2002</year>;(<issue>2</issue>):<elocation-id>CD003161</elocation-id>.<?supplied-pmid 12076472?><pub-id pub-id-type="pmid">12076472</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Morin</surname><given-names>CM</given-names></string-name>, <string-name><surname>Bootzin</surname><given-names>RR</given-names></string-name>, <string-name><surname>Buysse</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Edinger</surname><given-names>JD</given-names></string-name>, <string-name><surname>Espie</surname><given-names>CA</given-names></string-name>, <string-name><surname>Lichstein</surname><given-names>KL</given-names></string-name></person-group>. <article-title>Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004)</article-title>. <source>Sleep</source>. <year>2006</year>;<volume>29</volume>(<issue>11</issue>):<fpage>1398</fpage>-<lpage>1414</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/29.11.1398</pub-id><?supplied-pmid 17162986?><pub-id pub-id-type="pmid">17162986</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Morgenthaler</surname><given-names>T</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>M</given-names></string-name>, <string-name><surname>Alessi</surname><given-names>C</given-names></string-name>, <etal/>; <collab>American Academy of Sleep Medicine</collab></person-group>. <article-title>Practice parameters for the psychological and behavioral treatment of insomnia: an update: an American Academy of Sleep Medicine report</article-title>. <source>Sleep</source>. <year>2006</year>;<volume>29</volume>(<issue>11</issue>):<fpage>1415</fpage>-<lpage>1419</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/29.11.1415</pub-id><?supplied-pmid 17162987?><pub-id pub-id-type="pmid">17162987</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Riemann</surname><given-names>D</given-names></string-name>, <string-name><surname>Baglioni</surname><given-names>C</given-names></string-name>, <string-name><surname>Bassetti</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>European guideline for the diagnosis and treatment of insomnia</article-title>. <source>J Sleep Res</source>. <year>2017</year>;<volume>26</volume>(<issue>6</issue>):<fpage>675</fpage>-<lpage>700</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12594</pub-id><?supplied-pmid 28875581?><pub-id pub-id-type="pmid">28875581</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Qaseem</surname><given-names>A</given-names></string-name>, <string-name><surname>Kansagara</surname><given-names>D</given-names></string-name>, <string-name><surname>Forciea</surname><given-names>MA</given-names></string-name>, <string-name><surname>Cooke</surname><given-names>M</given-names></string-name>, <string-name><surname>Denberg</surname><given-names>TD</given-names></string-name>; <collab>Clinical Guidelines Committee of the American College of Physicians</collab></person-group>. <article-title>Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians</article-title>. <source>Ann Intern Med</source>. <year>2016</year>;<volume>165</volume>(<issue>2</issue>):<fpage>125</fpage>-<lpage>133</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M15-2175</pub-id><?supplied-pmid 27136449?><pub-id pub-id-type="pmid">27136449</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Asarnow</surname><given-names>LD</given-names></string-name>, <string-name><surname>Manber</surname><given-names>R</given-names></string-name></person-group>. <article-title>Cognitive behavioral therapy for insomnia in depression</article-title>. <source>Sleep Med Clin</source>. <year>2019</year>;<volume>14</volume>(<issue>2</issue>):<fpage>177</fpage>-<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsmc.2019.01.009</pub-id><?supplied-pmid 31029185?><pub-id pub-id-type="pmid">31029185</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ashworth</surname><given-names>DK</given-names></string-name>, <string-name><surname>Sletten</surname><given-names>TL</given-names></string-name>, <string-name><surname>Junge</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>A randomized controlled trial of cognitive behavioral therapy for insomnia: an effective treatment for comorbid insomnia and depression</article-title>. <source>J Couns Psychol</source>. <year>2015</year>;<volume>62</volume>(<issue>2</issue>):<fpage>115</fpage>-<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.1037/cou0000059</pub-id><?supplied-pmid 25867693?><pub-id pub-id-type="pmid">25867693</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wagley</surname><given-names>JN</given-names></string-name>, <string-name><surname>Rybarczyk</surname><given-names>B</given-names></string-name>, <string-name><surname>Nay</surname><given-names>WT</given-names></string-name>, <string-name><surname>Danish</surname><given-names>S</given-names></string-name>, <string-name><surname>Lund</surname><given-names>HG</given-names></string-name></person-group>. <article-title>Effectiveness of abbreviated CBT for insomnia in psychiatric outpatients: sleep and depression outcomes</article-title>. <source>J Clin Psychol</source>. <year>2013</year>;<volume>69</volume>(<issue>10</issue>):<fpage>1043</fpage>-<lpage>1055</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jclp.21927</pub-id><?supplied-pmid 23109266?><pub-id pub-id-type="pmid">23109266</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Manber</surname><given-names>R</given-names></string-name>, <string-name><surname>Bernert</surname><given-names>RA</given-names></string-name>, <string-name><surname>Suh</surname><given-names>S</given-names></string-name>, <string-name><surname>Nowakowski</surname><given-names>S</given-names></string-name>, <string-name><surname>Siebern</surname><given-names>AT</given-names></string-name>, <string-name><surname>Ong</surname><given-names>JC</given-names></string-name></person-group>. <article-title>CBT for insomnia in patients with high and low depressive symptom severity: adherence and clinical outcomes</article-title>. <source>J Clin Sleep Med</source>. <year>2011</year>;<volume>7</volume>(<issue>6</issue>):<fpage>645</fpage>-<lpage>652</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.1472</pub-id><?supplied-pmid 22171204?><pub-id pub-id-type="pmid">22171204</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Watanabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Furukawa</surname><given-names>TA</given-names></string-name>, <string-name><surname>Shimodera</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial</article-title>. <source>J Clin Psychiatry</source>. <year>2011</year>;<volume>72</volume>(<issue>12</issue>):<fpage>1651</fpage>-<lpage>1658</lpage>. doi:<pub-id pub-id-type="doi">10.4088/JCP.10m06130gry</pub-id><?supplied-pmid 21457679?><pub-id pub-id-type="pmid">21457679</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Christensen</surname><given-names>H</given-names></string-name>, <string-name><surname>Batterham</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Gosling</surname><given-names>JA</given-names></string-name>, <etal/></person-group>. <article-title>Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial</article-title>. <source>Lancet Psychiatry</source>. <year>2016</year>;<volume>3</volume>(<issue>4</issue>):<fpage>333</fpage>-<lpage>341</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2215-0366(15)00536-2</pub-id><?supplied-pmid 26827250?><pub-id pub-id-type="pmid">26827250</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cheng</surname><given-names>P</given-names></string-name>, <string-name><surname>Kalmbach</surname><given-names>DA</given-names></string-name>, <string-name><surname>Tallent</surname><given-names>G</given-names></string-name>, <string-name><surname>Joseph</surname><given-names>CL</given-names></string-name>, <string-name><surname>Espie</surname><given-names>CA</given-names></string-name>, <string-name><surname>Drake</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Depression prevention via digital cognitive behavioral therapy for insomnia: a randomized controlled trial</article-title>. <source>Sleep</source>. <year>2019</year>;<volume>42</volume>(<issue>10</issue>):<elocation-id>zsz150</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz150</pub-id><?supplied-pmid 31535688?><pub-id pub-id-type="pmid">31535688</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Muñoz</surname><given-names>RF</given-names></string-name>, <string-name><surname>Bunge</surname><given-names>EL</given-names></string-name></person-group>. <article-title>Prevention of depression worldwide: a wake-up call</article-title>. <source>Lancet Psychiatry</source>. <year>2016</year>;<volume>3</volume>(<issue>4</issue>):<fpage>306</fpage>-<lpage>307</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2215-0366(15)00555-6</pub-id><?supplied-pmid 26827251?><pub-id pub-id-type="pmid">26827251</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r26">
                <label>26</label>
                <mixed-citation publication-type="book"><person-group><collab>National Research Council and Institute of Medicine</collab></person-group>. <source>Preventing Mental, Emotional, and Behavioral Disorders among Young People: Progress and Possibilities.</source><publisher-name>National Academy Press</publisher-name>; <year>2009</year>.</mixed-citation>
              </ref>
              <ref id="yoi210068r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Reynolds</surname><given-names>CF</given-names><suffix>III</suffix></string-name></person-group>. <article-title>Prevention of depressive disorders: a brave new world</article-title>. <source>Depress Anxiety</source>. <year>2009</year>;<volume>26</volume>(<issue>12</issue>):<fpage>1062</fpage>-<lpage>1065</lpage>. doi:<pub-id pub-id-type="doi">10.1002/da.20644</pub-id><?supplied-pmid 19957277?><pub-id pub-id-type="pmid">19957277</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cuijpers</surname><given-names>P</given-names></string-name>, <string-name><surname>Pineda</surname><given-names>BS</given-names></string-name>, <string-name><surname>Quero</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Psychological interventions to prevent the onset of depressive disorders: a meta-analysis of randomized controlled trials</article-title>. <source>Clin Psychol Rev</source>. <year>2021</year>;<volume>83</volume>:<elocation-id>101955</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.cpr.2020.101955</pub-id><?supplied-pmid 33333441?><pub-id pub-id-type="pmid">33333441</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r29">
                <label>29</label>
                <mixed-citation publication-type="book"><person-group><collab>American Psychiatric Association</collab></person-group>. <source>Diagnostic and Statistical Manual of Mental Disorders</source>. <edition>5th ed</edition>. <publisher-name>American Psychiatric Association</publisher-name>; <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="yoi210068r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Turner</surname><given-names>L</given-names></string-name>, <string-name><surname>Shamseer</surname><given-names>L</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <etal/></person-group>. <article-title>Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2012</year>;<volume>11</volume>:<elocation-id>MR000030</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.MR000030.pub2</pub-id><?supplied-pmid 23152285?><pub-id pub-id-type="pmid">23152285</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Runyan</surname><given-names>CW</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>RM</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Risk and protective factors for fires, burns, and carbon monoxide poisoning in U.S. households</article-title>. <source>Am J Prev Med</source>. <year>2005</year>;<volume>28</volume>(<issue>1</issue>):<fpage>102</fpage>-<lpage>108</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amepre.2004.09.014</pub-id><?supplied-pmid 15626564?><pub-id pub-id-type="pmid">15626564</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>O’Malley</surname><given-names>AS</given-names></string-name>, <string-name><surname>Forrest</surname><given-names>CB</given-names></string-name></person-group>. <article-title>Beyond the examination room: primary care performance and the patient-physician relationship for low-income women</article-title>. <source>J Gen Intern Med</source>. <year>2002</year>;<volume>17</volume>(<issue>1</issue>):<fpage>66</fpage>-<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1525-1497.2002.10338.x</pub-id><?supplied-pmid 11903777?><pub-id pub-id-type="pmid">11903777</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Buysse</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ancoli-Israel</surname><given-names>S</given-names></string-name>, <string-name><surname>Edinger</surname><given-names>JD</given-names></string-name>, <string-name><surname>Lichstein</surname><given-names>KL</given-names></string-name>, <string-name><surname>Morin</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Recommendations for a standard research assessment of insomnia</article-title>. <source>Sleep</source>. <year>2006</year>;<volume>29</volume>(<issue>9</issue>):<fpage>1155</fpage>-<lpage>1173</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/29.9.1155</pub-id><?supplied-pmid 17040003?><pub-id pub-id-type="pmid">17040003</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Irwin</surname><given-names>M</given-names></string-name>, <string-name><surname>Artin</surname><given-names>KH</given-names></string-name>, <string-name><surname>Oxman</surname><given-names>MN</given-names></string-name></person-group>. <article-title>Screening for depression in the older adult: criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D)</article-title>. <source>Arch Intern Med</source>. <year>1999</year>;<volume>159</volume>(<issue>15</issue>):<fpage>1701</fpage>-<lpage>1704</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.159.15.1701</pub-id><?supplied-pmid 10448771?><pub-id pub-id-type="pmid">10448771</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Trauer</surname><given-names>JM</given-names></string-name>, <string-name><surname>Qian</surname><given-names>MY</given-names></string-name>, <string-name><surname>Doyle</surname><given-names>JS</given-names></string-name>, <string-name><surname>Rajaratnam</surname><given-names>SM</given-names></string-name>, <string-name><surname>Cunnington</surname><given-names>D</given-names></string-name></person-group>. <article-title>Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis</article-title>. <source>Ann Intern Med</source>. <year>2015</year>;<volume>163</volume>(<issue>3</issue>):<fpage>191</fpage>-<lpage>204</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M14-2841</pub-id><?supplied-pmid 26054060?><pub-id pub-id-type="pmid">26054060</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>van Straten</surname><given-names>A</given-names></string-name>, <string-name><surname>van der Zweerde</surname><given-names>T</given-names></string-name>, <string-name><surname>Kleiboer</surname><given-names>A</given-names></string-name>, <string-name><surname>Cuijpers</surname><given-names>P</given-names></string-name>, <string-name><surname>Morin</surname><given-names>CM</given-names></string-name>, <string-name><surname>Lancee</surname><given-names>J</given-names></string-name></person-group>. <article-title>Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis</article-title>. <source>Sleep Med Rev</source>. <year>2018</year>;<volume>38</volume>:<fpage>3</fpage>-<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2017.02.001</pub-id><?supplied-pmid 28392168?><pub-id pub-id-type="pmid">28392168</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lancee</surname><given-names>J</given-names></string-name>, <string-name><surname>van Straten</surname><given-names>A</given-names></string-name>, <string-name><surname>Morina</surname><given-names>N</given-names></string-name>, <string-name><surname>Kaldo</surname><given-names>V</given-names></string-name>, <string-name><surname>Kamphuis</surname><given-names>JH</given-names></string-name></person-group>. <article-title>Guided online or face-to-face cognitive behavioral treatment for insomnia: a randomized wait-list controlled trial</article-title>. <source>Sleep</source>. <year>2016</year>;<volume>39</volume>(<issue>1</issue>):<fpage>183</fpage>-<lpage>191</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.5344</pub-id><?supplied-pmid 26414893?><pub-id pub-id-type="pmid">26414893</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Taylor</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>AL</given-names></string-name>, <string-name><surname>Pruiksma</surname><given-names>KE</given-names></string-name>, <string-name><surname>Young-McCaughan</surname><given-names>S</given-names></string-name>, <string-name><surname>Nicholson</surname><given-names>K</given-names></string-name>, <string-name><surname>Mintz</surname><given-names>J</given-names></string-name>; <collab>STRONG STAR Consortium</collab></person-group>. <article-title>Internet and in-person cognitive behavioral therapy for insomnia in military personnel: a randomized clinical trial</article-title>. <source>Sleep</source>. <year>2017</year>;<volume>40</volume>(<issue>6</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsx075</pub-id><?supplied-pmid 28472528?><pub-id pub-id-type="pmid">28472528</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Irwin</surname><given-names>MR</given-names></string-name>, <string-name><surname>Olmstead</surname><given-names>R</given-names></string-name>, <string-name><surname>Carrillo</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Cognitive behavioral therapy vs. tai chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial</article-title>. <source>Sleep</source>. <year>2014</year>;<volume>37</volume>(<issue>9</issue>):<fpage>1543</fpage>-<lpage>1552</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.4008</pub-id><?supplied-pmid 25142571?><pub-id pub-id-type="pmid">25142571</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ferrari</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Somerville</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature</article-title>. <source>Psychol Med</source>. <year>2013</year>;<volume>43</volume>(<issue>3</issue>):<fpage>471</fpage>-<lpage>481</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0033291712001511</pub-id><?supplied-pmid 22831756?><pub-id pub-id-type="pmid">22831756</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Liao</surname><given-names>JM</given-names></string-name>, <string-name><surname>Stack</surname><given-names>CB</given-names></string-name></person-group>. <article-title>Annals understanding clinical research: implications of missing data due to dropout</article-title>. <source>Ann Intern Med</source>. <year>2017</year>;<volume>166</volume>(<issue>8</issue>):<fpage>596</fpage>-<lpage>598</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M17-0195</pub-id><?supplied-pmid 28241264?><pub-id pub-id-type="pmid">28241264</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cole</surname><given-names>MG</given-names></string-name>, <string-name><surname>Dendukuri</surname><given-names>N</given-names></string-name></person-group>. <article-title>Risk factors for depression among elderly community subjects: a systematic review and meta-analysis</article-title>. <source>Am J Psychiatry</source>. <year>2003</year>;<volume>160</volume>(<issue>6</issue>):<fpage>1147</fpage>-<lpage>1156</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.160.6.1147</pub-id><?supplied-pmid 12777274?><pub-id pub-id-type="pmid">12777274</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>van Zoonen</surname><given-names>K</given-names></string-name>, <string-name><surname>Buntrock</surname><given-names>C</given-names></string-name>, <string-name><surname>Ebert</surname><given-names>DD</given-names></string-name>, <etal/></person-group>. <article-title>Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions</article-title>. <source>Int J Epidemiol</source>. <year>2014</year>;<volume>43</volume>(<issue>2</issue>):<fpage>318</fpage>-<lpage>329</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ije/dyt175</pub-id><?supplied-pmid 24760873?><pub-id pub-id-type="pmid">24760873</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cuijpers</surname><given-names>P</given-names></string-name>, <string-name><surname>van Straten</surname><given-names>A</given-names></string-name>, <string-name><surname>Smit</surname><given-names>F</given-names></string-name>, <string-name><surname>Mihalopoulos</surname><given-names>C</given-names></string-name>, <string-name><surname>Beekman</surname><given-names>A</given-names></string-name></person-group>. <article-title>Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions</article-title>. <source>Am J Psychiatry</source>. <year>2008</year>;<volume>165</volume>(<issue>10</issue>):<fpage>1272</fpage>-<lpage>1280</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07091422</pub-id><?supplied-pmid 18765483?><pub-id pub-id-type="pmid">18765483</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ormel</surname><given-names>J</given-names></string-name>, <string-name><surname>Cuijpers</surname><given-names>P</given-names></string-name>, <string-name><surname>Jorm</surname><given-names>AF</given-names></string-name>, <string-name><surname>Schoevers</surname><given-names>R</given-names></string-name></person-group>. <article-title>Prevention of depression will only succeed when it is structurally embedded and targets big determinants</article-title>. <source>World Psychiatry</source>. <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>111</fpage>-<lpage>112</lpage>. doi:<pub-id pub-id-type="doi">10.1002/wps.20580</pub-id><?supplied-pmid 30600627?><pub-id pub-id-type="pmid">30600627</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ebert</surname><given-names>DD</given-names></string-name>, <string-name><surname>Cuijpers</surname><given-names>P</given-names></string-name></person-group>. <article-title>It is time to invest in the prevention of depression</article-title>. <source>JAMA Netw Open</source>. <year>2018</year>;<volume>1</volume>(<issue>2</issue>):<elocation-id>e180335</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.0335</pub-id><?supplied-pmid 30646081?><pub-id pub-id-type="pmid">30646081</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cuijpers</surname><given-names>P</given-names></string-name>, <string-name><surname>Beekman</surname><given-names>AT</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>CF</given-names><suffix>III</suffix></string-name></person-group>. <article-title>Preventing depression: a global priority</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>(<issue>10</issue>):<fpage>1033</fpage>-<lpage>1034</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2012.271</pub-id><?supplied-pmid 22416097?><pub-id pub-id-type="pmid">22416097</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Arnedt</surname><given-names>JT</given-names></string-name>, <string-name><surname>Conroy</surname><given-names>DA</given-names></string-name>, <string-name><surname>Mooney</surname><given-names>A</given-names></string-name>, <string-name><surname>Furgal</surname><given-names>A</given-names></string-name>, <string-name><surname>Sen</surname><given-names>A</given-names></string-name>, <string-name><surname>Eisenberg</surname><given-names>D</given-names></string-name></person-group>. <article-title>Telemedicine versus face-to-face delivery of cognitive behavioral therapy for insomnia: a randomized controlled non-inferiority trial</article-title>. <source>Sleep.</source><year>2020</year>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsaa136</pub-id><?supplied-pmid 32658298?><pub-id pub-id-type="pmid">32658298</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McCurry</surname><given-names>SM</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>W</given-names></string-name>, <string-name><surname>Von Korff</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Effect of telephone cognitive behavioral therapy for insomnia in older adults with osteoarthritis pain: a randomized clinical trial</article-title>. <source>JAMA Intern Med</source>. <year>2021</year>;<volume>181</volume>(<issue>4</issue>):<fpage>530</fpage>-<lpage>538</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2020.9049</pub-id><?supplied-pmid 33616613?><pub-id pub-id-type="pmid">33616613</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McCall</surname><given-names>WV</given-names></string-name>, <string-name><surname>Benca</surname><given-names>RM</given-names></string-name>, <string-name><surname>Rosenquist</surname><given-names>PB</given-names></string-name>, <etal/></person-group>. <article-title>Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): a randomized clinical trial</article-title>. <source>Am J Psychiatry</source>. <year>2019</year>;<volume>176</volume>(<issue>11</issue>):<fpage>957</fpage>-<lpage>965</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2019.19030267</pub-id><?supplied-pmid 31537089?><pub-id pub-id-type="pmid">31537089</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Irwin</surname><given-names>MR</given-names></string-name>, <string-name><surname>Vitiello</surname><given-names>MV</given-names></string-name></person-group>. <article-title>Implications of sleep disturbance and inflammation for Alzheimer’s disease dementia</article-title>. <source>Lancet Neurol</source>. <year>2019</year>;<volume>18</volume>(<issue>3</issue>):<fpage>296</fpage>-<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30450-2</pub-id><?supplied-pmid 30661858?><pub-id pub-id-type="pmid">30661858</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Grandner</surname><given-names>MA</given-names></string-name>, <string-name><surname>Williams</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Knutson</surname><given-names>KL</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>D</given-names></string-name>, <string-name><surname>Jean-Louis</surname><given-names>G</given-names></string-name></person-group>. <article-title>Sleep disparity, race/ethnicity, and socioeconomic position</article-title>. <source>Sleep Med</source>. <year>2016</year>;<volume>18</volume>:<fpage>7</fpage>-<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2015.01.020</pub-id><?supplied-pmid 26431755?><pub-id pub-id-type="pmid">26431755</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Slavich</surname><given-names>GM</given-names></string-name>, <string-name><surname>Irwin</surname><given-names>MR</given-names></string-name></person-group>. <article-title>From stress to inflammation and major depressive disorder: a social signal transduction theory of depression</article-title>. <source>Psychol Bull</source>. <year>2014</year>;<volume>140</volume>(<issue>3</issue>):<fpage>774</fpage>-<lpage>815</lpage>. doi:<pub-id pub-id-type="doi">10.1037/a0035302</pub-id><?supplied-pmid 24417575?><pub-id pub-id-type="pmid">24417575</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Morin</surname><given-names>CM</given-names></string-name>, <string-name><surname>Vallières</surname><given-names>A</given-names></string-name>, <string-name><surname>Guay</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>301</volume>(<issue>19</issue>):<fpage>2005</fpage>-<lpage>2015</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2009.682</pub-id><?supplied-pmid 19454639?><pub-id pub-id-type="pmid">19454639</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Irwin</surname><given-names>MR</given-names></string-name>, <string-name><surname>Cole</surname><given-names>JC</given-names></string-name>, <string-name><surname>Nicassio</surname><given-names>PM</given-names></string-name></person-group>. <article-title>Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age</article-title>. <source>Health Psychol</source>. <year>2006</year>;<volume>25</volume>(<issue>1</issue>):<fpage>3</fpage>-<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1037/0278-6133.25.1.3</pub-id><?supplied-pmid 16448292?><pub-id pub-id-type="pmid">16448292</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Blom</surname><given-names>K</given-names></string-name>, <string-name><surname>Tarkian Tillgren</surname><given-names>H</given-names></string-name>, <string-name><surname>Wiklund</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Internet- vs. group-delivered cognitive behavior therapy for insomnia: a randomized controlled non-inferiority trial</article-title>. <source>Behav Res Ther</source>. <year>2015</year>;<volume>70</volume>:<fpage>47</fpage>-<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brat.2015.05.002</pub-id><?supplied-pmid 25981329?><pub-id pub-id-type="pmid">25981329</pub-id></mixed-citation>
              </ref>
              <ref id="yoi210068r57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bastien</surname><given-names>CH</given-names></string-name>, <string-name><surname>Morin</surname><given-names>CM</given-names></string-name>, <string-name><surname>Ouellet</surname><given-names>MC</given-names></string-name>, <string-name><surname>Blais</surname><given-names>FC</given-names></string-name>, <string-name><surname>Bouchard</surname><given-names>S</given-names></string-name></person-group>. <article-title>Cognitive-behavioral therapy for insomnia: comparison of individual therapy, group therapy, and telephone consultations</article-title>. <source>J Consult Clin Psychol</source>. <year>2004</year>;<volume>72</volume>(<issue>4</issue>):<fpage>653</fpage>-<lpage>659</lpage>. doi:<pub-id pub-id-type="doi">10.1037/0022-006X.72.4.653</pub-id><?supplied-pmid 15301650?><pub-id pub-id-type="pmid">15301650</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-YOI210068-1">
              <supplementary-material id="note-YOI210068-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol and Statistical Analysis Plan
</p>
                </caption>
                <media xlink:href="jamapsychiatry-e213422-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eMethods.</bold> Supplemental Methods</p>
                  <p><bold>eResults.</bold> Supplemental Results</p>
                  <p><bold>eTable 1.</bold> Number and Proportion of Participants Retained at Each Assessment Interval</p>
                  <p><bold>eTable 2.</bold> Characteristics of Participants by Treatment Group as a Function of Discontinuation, at Completion of Treatment</p>
                  <p><bold>eTable 3.</bold> Characteristics of Participants by Treatment Group as a Function of Discontinuation, at 24 Months Follow-up</p>
                  <p><bold>eTable 4.</bold> Characteristics of Participants by Treatment Group, at Entry Into Extended Follow-up</p>
                  <p><bold>eTable 5.</bold> Probability of Incident Depression During 36-Month Follow-up in CBT-I Treatment Group, as Compared to SET, Expressed as Hazard Ratio (HR) With 95% CI</p>
                  <p><bold>eTable 6.</bold> Probability of Incident Depression in Participants With Sustained Insomnia Remission, as Compared to No Sustained Insomnia Remission, Over 36 Months Follow-up, Expressed as Hazard Ratio (HR) With 95% CI</p>
                  <p><bold>eFigure 1.</bold> Time to Incident Depression Event by Treatment Group in Sample With DSM-5 Insomnia Disorder</p>
                  <p><bold>eFigure 2.</bold> Time to Incident Depression Event by Insomnia Remission Sustained Over 36 Months</p>
                  <p><bold>eFigure 3.</bold> Time to Incident Depression Event by Percentage Duration Insomnia Remission</p>
                  <p>
eReferences
</p>
                </caption>
                <media xlink:href="jamapsychiatry-e213422-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamapsychiatry-e213422-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
